Acetaminophen Aspirin Caffeine

證據等級: L5

預測適應症: 0 個

Acetaminophen + Aspirin + Caffeine: Evaluation Report — No Repurposing Candidates Identified

One-Sentence Summary

Acetaminophen + Aspirin + Caffeine is a classic analgesic combination widely used for headache and mild-to-moderate pain relief. The TxGNN model returned no repurposing candidates for this drug combination, and no Taiwan regulatory records were found for this exact formulation string. The evaluation cannot proceed until the underlying data pipeline issues are resolved.

Quick Overview

Item	Content
Original Indication	Analgesic / antipyretic combination (headache, pain relief)
Predicted New Indication	None identified by TxGNN
TxGNN Prediction Score	N/A
Evidence Level	L5 — No candidates returned
Taiwan Market Status	Not marketed
Number of Licenses	0
Recommended Decision	Hold

Why No Prediction Was Generated

This Evidence Pack contains an empty predicted_indications array, meaning TxGNN produced no repurposing candidates for this drug. Three structural issues likely explain this outcome:

1. Multi-ingredient combination format mismatch TxGNN operates on single-ingredient entities in its knowledge graph. Passing a semicolon-separated string — “ACETAMINOPHEN; ASPIRIN; CAFFEINE” — almost certainly fails to match any node in the graph, causing the prediction step to return nothing. This is a query formatting issue, not an indication that no repurposing potential exists.

2. Missing DrugBank ID The Evidence Pack records drugbank_id: null. The DrugBank ID is the primary identifier used to anchor a drug within the knowledge graph. Without it, the KG traversal and scoring steps cannot run correctly.

3. No regulatory records found The Taiwan FDA query returned zero results for the combined string. These three drugs are individually registered and widely available, suggesting the lookup used the full combination name rather than individual INN lookups, causing a false-negative match.

Path forward: Re-run the pipeline by splitting the combination into three separate queries — one per active ingredient — then aggregate and intersect the resulting predictions.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The empty prediction list reflects a data pipeline formatting issue rather than a genuine absence of repurposing signal. No meaningful evaluation can be performed until each ingredient is processed individually through the TxGNN pipeline.

To proceed, the following is needed:

Resolve the multi-ingredient query: Re-run TxGNN predictions separately for acetaminophen, aspirin, and caffeine using their individual INN names and DrugBank IDs
Restore DrugBank IDs: Query DrugBank API for each component to retrieve drugbank_id, mechanism of action, and toxicity data
Repeat Taiwan FDA lookup: Search regulatory records using individual INN names to obtain license data, approved indications, and package insert warnings
Repeat DDI query: Re-query drug–drug interaction database per component
Aggregate results: After per-component predictions are available, consolidate into a combined Evidence Pack and generate a new repurposing report
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.